An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy
Advanced Materials · 2023
DOI: 10.1002/adma.202303831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Xing-Jie Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Regional Key Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Anti‐PD‐L1 monoclonal antibody has achieved substantial success in tumor immunotherapy by T‐cells activation. However, the excessive accumulation of extracellular matrix components induced by unsatisfactory T‐cells infiltration and poor tumor penetration of antibodies make it challenging to realize efficient tumor immunotherapy. Herein, a peptide‐based bispecific nanoblocker (BNB) strategy is reported for in situ construction of CXCR4/PD‐L1 targeted nanoclusters on the surface of tumor cells that are capable of boosting T‐cells infiltration through CXCR4 blockage and enhancing T‐cells activation by PD‐L1 occupancy, ultimately realizing high‐performance tumor immunotherapy. Briefly, the BNB strategy selectively recognizes and bonds CXCR4/PD‐L1 with deep tumor penetration, which rapidly self‐assembles into nanoclusters on the surface of tumor cells. Compared to the traditional bispecific antibody, BNB exhibits an intriguing metabolic behavior, that is, the elimination half‐life ( t 1/2 ) of BNB in the tumor is 69.3 h which is ≈50 times longer than that in the plasma (1.4 h). The higher tumor accumulation and rapid systemic clearance overcome potential systemic side effects. Moreover, the solid tumor stress generated by excessive extracellular matrix components is substantially reduced to 44%, which promotes T‐cells infiltration and activation for immunotherapy efficacy. Finally, these findings substantially strengthen and extend clinical applications of PD‐1/PD‐L1 immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou, 450052, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, China.
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, China.
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, 150001, China.
- Department of Urology, Harbin Medical University Cancer Hospital, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, 150001, China.
ORCID-Profile: Hao Wang
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Regional Key Project of the National Natural Science Foundation of China
- Overseas High-end Talents Introduction Program
- National Key Research and Development Program of China
Zitieren
APA
Hu, X. J., Zhang, N. Y., Hou, D. Y., Wang, Z. J., Wang, M. D., Yi, L., Song, Z. Z., Liang, J. X., Li, X. P., An, H. W., Xu, W., & Wang, H. (2023). An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202303831
Vancouver
Hu XJ, Zhang NY, Hou DY, Wang ZJ, Wang MD, Yi L, et al. An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy. Advanced Materials. 2023. doi:10.1002/adma.202303831
BibTeX
@article{Hu2023,
author = {Hu, Xing-Jie and Zhang, Ni-Yuan and Hou, Da-Yong and Wang, Zhi-Jia and Wang, Man-Di and Yi, Li and Song, Zhang-Zhi and Liang, Jian-Xiao and Li, Xiang-Peng and An, Hong-Wei and Xu, Wanhai and Wang, Hao},
title = {An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202303831}
}
EUVIMED